Developmental therapy for selectively targeting MEK-ERK pathway in cancer cells and tumor stromal compartment

选择性靶向癌细胞和肿瘤基质室中 MEK-ERK 通路的发育疗法

• 批准号: 10092258
• 负责人: Shihui Liu
• 金额: $ 42.9万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-07 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10092258
• 关键词: ANTXR2 gene; Address; Antigens; Antitumor Response; B-Lymphocytes; BRAF gene; Binding; Biodistribution; Blood capillaries; Brain; Cell Proliferation; Cell Survival; Cells; Cytosol; Data; Development; Developmental Therapeutics Program; Endothelial Cells; Engineering; Ensure; FDA approved; Fibroblasts; Future; Genetic; Goals; Human; KRAS2 gene; Link; MAP Kinase Gene; MAP2K1 gene; MAPK8 gene; MEK inhibition; MEKs; Malignant Neoplasms; Matrix Metalloproteinases; Metastatic Melanoma; Modeling; Molecular; Morphogenesis; Mus; Mutation; Names; Normal Cell; Oncogenic; Pathway interactions; Patients; Peptide Hydrolases; Physiological; Proteins; Ras/Raf; Regulatory T-Lymphocyte; Role; Side; Signal Transduction; Solid Neoplasm; Specificity; Stromal Cells; Stromal Neoplasm; Structure; System; Targeted Toxins; Therapeutic; Therapeutic Index; Tissues; Toxic effect; Toxin; Tumor-associated macrophages; Urokinase; Variant; anthrax lethal factor; anthrax toxin; anthrax toxin receptors; base; cancer cell; carcinogenicity; cell type; clinical development; clinical efficacy; driver mutation; gain of function; genetic manipulation; in vivo; inhibitor/antagonist; insight; loss of function; microbial; neoplastic cell; novel; p38 Mitogen Activated Protein Kinase; pathogenic bacteria; pre-clinical; receptor; side effect; small molecule; small molecule inhibitor; small molecule therapeutics; targeted treatment; therapeutic development; tumor; tumor microenvironment; tumorigenesis

Project Summary/Abstract Carcinogenic mutations in the RAS-RAF-MEK-ERK pathway are present in 46% of all human cancers. This has inspired the successful development of many small molecule BRAF and MEK pathway inhibitors. These agents are currently FDA approved for the treatment of metastatic melanomas containing BRAF mutations. Although BRAF and MEK inhibitors have shown some benefits to patients, these “targeted” therapeutics have a very low therapeutic index, since these small molecules also target normal cells, causing undesirable, even fatal, side effects. Moreover, whether the clinical efficacy of these inhibitors is via direct effects on the tumor or through modulation of the tumor stromal compartment remains elusive. In this application, we address the above critical unmet needs and will develop a potent and highly tumor-selective MEK inactivator by engineering an anthrax toxin-based protein delivery system. Through manipulating the expression of the toxin receptor on specific tumor stromal cell types, we will also delineate how stromal MEK inhibition regulates tumor development. We propose two parallel, but independent Specific Aims to achieve these goals. In Aim 1, we will generate an anthrax toxin-based, highly tumor-selective MEK inactivator and evaluate its anti-tumor activity in a variety of tumor models. This MEK inactivator specifically binds to the major toxin receptor CMG2 (capillary morphogenesis protein-2) on tumor cells and tumor stromal cells. Specificity is ensured through strict reliance on the simultaneous presence of two distinct tumor-associated proteases, MMPs and urokinase, to gain entry into tumor cells and tumor stromal cells. Once inside, it inactivates MEK-ERK signaling, achieving potent selective targeting. In Aim 2, we will employ our unique tumor-host-toxin system to determine the roles of MEK-ERK signaling in tumor stromal cells in tumor development and in the toxin’s tumor targeting. We have previously established a genetic system allowing CMG2 gain-of-function or loss-of-function in various specific cell types in the tumor microenvironment. Thus, we hypothesize that a genetic manipulation of CMG2 expression on cancer cells and various tumor stromal cells in the whole body of CMG2-/- mice will provide the first tractable genetic system to delineate the role of specific cell types in the tumor microenvironment. Therefore, in this Aim 2, we will determine the roles of selected tumor stromal cell types including tumor endothelial cells (EC), tumor-associated macrophages (TAM), cancer-associated fibroblasts (CAF), B cells, and regulatory T cells (Treg), and the molecular mechanisms of MEK-ERK inhibition in these cells in tumor development. Upon completion of these studies, we expect to have developed a highly potent, tumor-selective MEK inactivator as a novel tumor-targeted therapeutic. These studies will also unambiguously determine the role of MEK-ERK signaling in both the tumor and the stroma, thereby validating and identifying specific tumor stromal cell types as targets for future therapeutics development.

项目摘要/摘要 RAS-RAF-MEK-ERK通路的致癌突变存在于46%的人类癌症中。这有 启发了许多小分子BRAF和MEK途径抑制剂的成功开发。这些特工 目前FDA批准用于治疗含有BRAF突变的转移性黑色素瘤。虽然 BRAF和MEK抑制剂已经显示出对患者的一些好处，这些“靶向”治疗药物的疗效非常低 治疗指数，因为这些小分子也针对正常细胞，导致不良的，甚至致命的副作用 效果。此外，无论这些抑制物的临床疗效是通过对肿瘤的直接作用还是通过 肿瘤间质间隔的调节仍然难以捉摸。在本应用程序中，我们解决了上述关键问题 并将通过设计一种炭疽病来开发一种有效的、对肿瘤具有高度选择性的MEK灭活剂 以毒素为基础的蛋白质输送系统。通过调控肿瘤特异性毒素受体的表达 关于间质细胞类型，我们还将描述间质MEK抑制如何调节肿瘤的发展。 我们提出了两个平行但独立的具体目标来实现这些目标。在目标1中，我们将生成一个 炭疽毒素为基础的高度肿瘤选择性的MEK灭活剂，并评价其在多种 肿瘤模型。这种MEK灭活剂与主要毒素受体CMG2(毛细血管形态发生)特异性结合 蛋白-2)在肿瘤细胞和肿瘤基质细胞上表达。通过严格依赖于 同时存在两种不同的肿瘤相关蛋白--MMPs和尿激酶，以获得进入肿瘤的机会 细胞和肿瘤间质细胞。一旦进入，它就会使MEK-ERK信号失活，实现有效的选择性靶向。 在目标2中，我们将使用我们独特的肿瘤-宿主-毒素系统来确定MEK-ERK信号在 肿瘤间质细胞参与肿瘤的发展和毒素的肿瘤靶向。我们之前已经建立了一个 允许CMG2在肿瘤中各种特定细胞类型中功能获得或功能丧失的遗传系统 微环境。因此，我们假设对癌细胞和癌细胞上CMG2表达的基因操作 CMG2-/-小鼠体内的各种肿瘤基质细胞将提供第一个易于处理的遗传系统 描述特定细胞类型在肿瘤微环境中的作用。因此，在这个目标2中，我们将确定 某些肿瘤基质细胞类型的作用，包括肿瘤内皮细胞(EC)、肿瘤相关 巨噬细胞()、肿瘤相关成纤维细胞(CAF)、B细胞和调节性T细胞(Treg)，以及 MEK-ERK在这些细胞中抑制肿瘤发生的分子机制。在完成这些任务后 在研究中，我们希望开发出一种高效的、肿瘤选择性的MEK失活剂，作为一种新的肿瘤靶向 有治疗作用。这些研究还将明确确定MEK-ERK信号在两种肿瘤中的作用 和间质，从而验证和识别特定的肿瘤间质细胞类型作为未来的目标 治疗学的发展。